Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009–2016)

Randall K Thomas¹
Ron Melton¹
Penny A Asbell²

¹Educators in Primary Eye Care, LLC, Concord, NC, USA; ²Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN, USA

Background: The Antibiotic Resistance Monitoring in Ocular micRoorganisms study is an ongoing surveillance study that tracks antibiotic resistance among bacterial isolates from ocular infections across the United States. We report antibiotic resistance rates and trends from 2009 through 2016.

Materials and methods: Staphylococcus aureus, coagulase-negative staphylococci (CoNS), Streptococcus pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae from various ocular infections were obtained from participating United States centers. Isolates were sent to a central laboratory for determination of antibiotic resistance profiles. Minimum inhibitory concentrations were determined by broth microdilution according to the Clinical and Laboratory Standards Institute for drugs from more than ten antibiotic classes, and isolates were classified as susceptible or resistant based on systemic breakpoints, wherever available. Resistance rates were also evaluated based on decade of patient life and longitudinally over the 8-year time period.

Results: A total of 1,695 S. aureus, 1,475 CoNS, 474 S. pneumoniae, 586 H. influenzae, and 599 P. aeruginosa were collected from 87 sites. Resistance was high among staphylococci and pneumococci, with methicillin resistance detected in 621 (36.6%) S. aureus and 717 (48.6%) CoNS isolates. Multidrug resistance (≥3 drug classes) was observed among staphylococci, particularly in methicillin-resistant (MR) isolates (MR S. aureus [MRSA]: 76.2%; MR CoNS [MRCoNS]: 73.5%). Differences in methicillin resistance among staphylococci were observed based on patient age, with higher rates observed in older patients (P<0.0001). For certain organism-antibiotic combinations, there were significant changes in resistance over time, including a decrease in methicillin resistance among S. aureus (but not CoNS); no notable trends were observed for S. pneumoniae.

Conclusion: Antibiotic resistance was prevalent among gram-positive organisms, and MR staphylococcal isolates were more likely to be multidrug resistant. Although a small decrease in methicillin resistance was observed among S. aureus over time, the continued high prevalence of in vitro methicillin resistance should be considered when treating patients with ocular infections.

Keywords: ophthalmic infections, bacterial pathogens, topical antimicrobials, multidrug resistance, methicillin resistance

Introduction

Bacterial resistance to antibiotics, acquired primarily through genetic mutations, is high globally, with several contributing factors identified.¹ Studies have shown that practices such as overprescription of antibiotics, use of inappropriate dosing regimens, and widespread agricultural use of antibiotics have contributed significantly to the problem of antibiotic resistance, with resistant bacteria posing considerable risk to
the resolution of systemic infections. Antibiotic resistance has also been observed among pathogens causing ocular infections specifically, with factors such as empirical prescribing of antibiotics, short-term exposure to antibiotics, and repeated exposure to the same antibiotic identified as contributing to resistance of ocular pathogens, as well as leading to changes in resident ocular flora. Antimicrobial prophylaxis, used for the prevention of endophthalmitis and postoperative infection in patients undergoing ocular surgery, could also contribute to increased resistance rates among ocular pathogens.

Staphylococcus aureus and coagulase-negative staphylococci (CoNS; most frequently Staphylococcus epidermidis), which colonize the surfaces of the eyes and eyelids, are important contributors to ocular infections. While S. aureus accounts for a large proportion of bacterial keratitis cases (>25%), CoNS accounts for the majority (>30%) of endophthalmitis cases, especially acute episodes that develop after cataract surgery, and both are increasingly recognized as common causes of conjunctivitis when present above established quantitative levels. Similarly, both Streptococcus pneumoniae and Haemophilus influenzae are commonly isolated from patients with bacterial conjunctivitis, especially children, and the significant ocular pathogen Pseudomonas aeruginosa is a leading cause of bacterial keratitis in contact lens wearers.

Ocular infections caused by these common bacterial pathogens are treated with a wide variety of antibiotics. Infection with resistant organisms can complicate antibiotic selection, increasing the risk of treatment failure with potentially sight-threatening consequences. Since many antibiotics are also prescribed systemically to treat a broad spectrum of other bacterial infections, cross-resistance can complicate treatment further. Currently, besifloxacin, a chlorofluoroquinolone indicated for the treatment of bacterial conjunctivitis, is the only antibiotic exclusively formulated for topical ophthalmic use. Since its administration is solely topical, resistance to besifloxacin has the potential to be lower than that observed for other fluoroquinolones, which are also administered systemically.

The WHO Global Action Plan on Antimicrobial Resistance emphasizes the importance of antibiotic resistance surveillance programs and research to strengthen the existing knowledge base and combat growing antimicrobial resistance. Few multicenter studies have surveyed rates of antibiotic resistance specifically in ocular pathogens, with only the Ocular Tracking Resistance in the US Today (TRUST) and Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance programs publishing nationwide results in the recent past. The ARMOR study, which was initiated in 2009, is currently the only ongoing national surveillance study specifically designed to track in vitro antibacterial resistance rates among ocular pathogens. With collection of isolates over an 8-year period, the dataset is sufficiently large to allow for subanalyses to determine how factors like age impact resistance rates, as well as how resistance rates may change over time. An understanding of resistance patterns among ocular pathogens can help clinicians select appropriate treatment strategies, improve pre- and postoperative management, and positively impact patient outcomes. Periodic updates of the ARMOR surveillance study have been published previously. Here, we report cumulative resistance profiles and trends from 2009 through 2016.

Materials and methods
Study design and sample collection
The ARMOR study methodology has been described in detail previously. Briefly, clinically relevant isolates of S. aureus, CoNS, S. pneumoniae, H. influenzae, and P. aeruginosa cultured from ocular infections were submitted by US sites as part of the ongoing ARMOR study. Isolates of the requested species had to meet the clinical site’s criteria for “significant pathogen” and be collected from ocular tissue sources (ie, eye, conjunctiva, cornea, aqueous humor, and vitreous humor). From 2009 to 2013, each participating site was invited to submit up to 65 ocular isolates per collection year, including no more than 20 S. aureus, 20 CoNS, 5 S. pneumoniae, 5 H. influenzae, and 15 P. aeruginosa; whereas from 2014 to 2016, sites were invited to submit a maximum of 50 isolates per collection year of S. aureus, CoNS, S. pneumoniae, H. influenzae, and P. aeruginosa, with no more than 12 isolates of any given species. The central laboratory in ARMOR obtained pure subcultures of bacterial isolates from each of the clinical sites, although not all sites submitted samples throughout all 8 years. Enrolled sites included community hospitals, academic/university hospitals, specialty/ocular centers, and reference laboratories. Duplicate isolates from the same patient (same genus and species) were excluded from the study. Ocular pathogens collected from January 1, 2009 through December 31, 2016 were analyzed herein. As this was a laboratory study, informed consent and institutional review board approval were not required; Health Insurance Portability and Accountability Act compliance did not apply given the initial ocular samples were taken as part of routine medical care unrelated to this study, and no patient-identifying information was provided.
Susceptibility to antibiotics and testing procedures

Bacterial isolates collected were sent to a central laboratory (Eurofins Medinet, Chantilly, VA, USA [2009–2013]; IHMA, Inc., Schaumburg, IL, USA [2014–2016]) for species confirmation and tested by the broth microdilution method in accordance with Clinical and Laboratory Standards Institute (CLSI) procedures. Briefly, isolates (~5×10^5 CFU/mL) were grown in 96-well microtiter panels in the presence of titrated antibiotic concentrations and incubated for 16–20 hours (staphylococci and \textit{P. aeruginosa}, both in cation-adjusted Mueller-Hinton broth [CAMHB]) or 20–24 hours (\textit{S. pneumoniae} in CAMHB supplemented with 3% lysed horse blood, and \textit{H. influenzae} in Haemophilus test medium) in ambient air at 35°C. The minimum inhibitory concentration (MIC), defined as the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism, was determined for each isolate by comparing growth in control wells (no antibiotic) to growth in wells that contained varying antibiotic concentrations. Lower MICs are indicative of higher in vitro antibiotic potency. Susceptibility testing was conducted using frozen microtiter panels containing various antibiotics from ten classes, namely, fluoroquinolones (moxifloxacin, gatifloxacin, levofloxacin, ofloxacin, ciprofloxacin, and besifloxacin), a macrolide (azithromycin), an aminoglycoside (tobramycin), a lincosamide (clindamycin), penicillins (oxacillin/penicillin), a folate pathway inhibitor (trimethoprim), a polypeptide (polymyxin B), a phenicol (chloramphenicol), a glycopeptide (vancomycin), and a tetracycline (tetracycline); not all drugs were tested in all years of the study period. Isolates were classified as resistant (included both intermediate and full resistance) or susceptible to an antibiotic using systemic breakpoints defined by the CLSI, wherever available, to interpret MICs. For staphylococcal isolates, susceptibility to oxacillin was used to categorize isolates as methicillin-resistant (MR) or methicillin-susceptible (MS). Susceptibility and resistance of \textit{S. pneumoniae} isolates to penicillin were determined using the breakpoint for oral penicillin. Isolates resistant to chloramphenicol (6.1%), trimethoprim (4.4%), and tetracycline (4.3%), and all were susceptible to vancomycin. Compared to MS \textit{S. aureus} (MSSA) isolates, which

Statistical analyses

A one-way ANOVA was used to evaluate antibiotic resistance by patient’s age categorized by decade of life. Since not all antibiotic classes were tested in each of the 8 years of the study period, the ANOVA used the means of the percentages of drug classes to which each isolate of a species or species group was resistant. Tukey’s honestly significant difference (HSD) test for pairwise differences (comparison between all possible pairs of means obtained for every patient-age decade) used the \(P<0.05\) criterion for statistical significance unless otherwise indicated, and was performed when ANOVAs showed significance at the \(P<0.05\) level. Differences in methicillin resistance among staphylococcal isolates, specifically by decade of life, were assessed using a chi-squared test. Longitudinal trends in antibiotic resistance over the study period were analyzed using the Cochran-Armitage test for linear trends in a proportion. Statistical testing was performed using Statistix 10 (Analytical Software, Tallahassee, FL, USA).

Results

Source of isolates

From January 1, 2009 through December 31, 2016, a total of 4,829 isolates (1,695 \textit{S. aureus}, 1,475 CoNS, 474 \textit{S. pneumoniae}, 586 \textit{H. influenzae}, and 599 \textit{P. aeruginosa}) were collected from 87 sites (46 community hospitals, 29 academic/university hospitals, nine specialty/ocular centers, and three reference laboratories) across 40 states. Of these, 2,124 (44.0%) and 2,261 (46.8%) isolates were obtained from male and female patients, respectively; patient’s gender was unknown for 444 (9.2%) isolates. A total of 3,934 (81.5%) isolates were obtained from patients with specified ages (<10 years: 868 [22.1%]; 10–19 years: 173 [4.4%]; 20–29 years: 249 [6.3%]; 30–39 years: 256 [6.5%]; 40–49 years: 345 [8.8%]; 50–59 years: 457 [11.6%]; 60–69 years: 443 [11.3%]; 70–79 years: 450 [11.4%]; 80–89 years: 463 [11.8%]; and 90–99 years: 230 [5.8%]). The precise anatomical infection source was known for 2,427 isolates (50.3%) of which 1,198 (49.4%) were obtained from the conjunctiva, 1,022 (42.1%) from the cornea, 69 (2.8%) from the aqueous humor, and 138 (5.7%) from the vitreous humor.

Cumulative antibiotic resistance rates

Tables 1–3 present in vitro antibiotic resistance profiles for the cumulative dataset by species/species group, including those for \textit{S. aureus} and CoNS by methicillin resistance phenotype.

Of the \textit{S. aureus} collected (Table 1), 60.6%, 35.8%, and 36.6% demonstrated in vitro resistance to azithromycin, ciprofloxacin, and methicillin (MR \textit{S. aureus} [MRSA]), respectively. While some resistance to tobramycin (17.4%) and clindamycin (15.4%) was noted, few \textit{S. aureus} isolates were resistant to chloramphenicol (6.1%), trimethoprim (4.4%), and tetracycline (4.3%), and all were susceptible to vancomycin. Compared to MS \textit{S. aureus} (MSSA) isolates, which
Table 1 Cumulative resistance profiles and MICs for *S. aureus* isolates

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th><em>S. aureus</em> All</th>
<th>%S</th>
<th>%R</th>
<th>MIC&lt;sub&gt;90&lt;/sub&gt;</th>
<th>MRSA</th>
<th>%S</th>
<th>%R</th>
<th>MIC&lt;sub&gt;90&lt;/sub&gt;</th>
<th>MSSA</th>
<th>%S</th>
<th>%R</th>
<th>MIC&lt;sub&gt;90&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vancomycin</td>
<td>1,695</td>
<td>100</td>
<td>0</td>
<td>1</td>
<td>621</td>
<td>100</td>
<td>0</td>
<td>1</td>
<td>1,074</td>
<td>100</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Besifloxacin</td>
<td>1,695 NA&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1</td>
<td>621 NA&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2</td>
<td>1,074 NA&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NA&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>1,495 65.9</td>
<td>34.1</td>
<td>8</td>
<td>543 26.7</td>
<td>73.3</td>
<td>16</td>
<td>952 88.2</td>
<td>11.8</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gatifloxacin</td>
<td>1,495 65.9</td>
<td>34.1</td>
<td>8</td>
<td>543 26.7</td>
<td>73.3</td>
<td>16</td>
<td>952 88.2</td>
<td>11.8</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>1,495 65.7</td>
<td>34.3</td>
<td>8</td>
<td>543 26.2</td>
<td>73.9</td>
<td>128</td>
<td>952 88.2</td>
<td>11.8</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>1,495 65.7</td>
<td>34.3</td>
<td>8</td>
<td>543 26.2</td>
<td>73.9</td>
<td>128</td>
<td>952 88.2</td>
<td>11.8</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>1,495 65.2</td>
<td>34.9</td>
<td>&gt;8</td>
<td>543 25.8</td>
<td>74.2</td>
<td>&gt;8</td>
<td>952 87.6</td>
<td>12.4</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azithromycin</td>
<td>1,495 65.4</td>
<td>34.6</td>
<td>&gt;8</td>
<td>543 25.8</td>
<td>74.2</td>
<td>&gt;8</td>
<td>952 87.6</td>
<td>12.4</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>1,495 93.9</td>
<td>6.1</td>
<td>8</td>
<td>543 89.5</td>
<td>10.5</td>
<td>16</td>
<td>952 96.4</td>
<td>3.6</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clindamycin</td>
<td>1,495 84.6</td>
<td>15.4</td>
<td>&gt;2</td>
<td>621 69.7</td>
<td>30.3</td>
<td>&gt;2</td>
<td>1,074 93.2</td>
<td>6.8</td>
<td>0.25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methicillin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1,495 63.4</td>
<td>36.6</td>
<td>&gt;2</td>
<td>621 0</td>
<td>100</td>
<td>&gt;4</td>
<td>1,074 100</td>
<td>0</td>
<td>0.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetracycline</td>
<td>419 95.7</td>
<td>4.3</td>
<td>0.5</td>
<td>103 90.3</td>
<td>9.7</td>
<td>4</td>
<td>316 97.5</td>
<td>2.5</td>
<td>0.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobramycin</td>
<td>1,495 82.6</td>
<td>17.4</td>
<td>128</td>
<td>621 58.9</td>
<td>41.1</td>
<td>256</td>
<td>1,074 96.3</td>
<td>3.7</td>
<td>0.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>1,495 95.7</td>
<td>4.4</td>
<td>4</td>
<td>543 94.1</td>
<td>5.9</td>
<td>2</td>
<td>952 96.5</td>
<td>3.5</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *Oxacillin was used as a surrogate for methicillin.* *Clinical and Laboratory Standards Institute interpretive breakpoints are not available.* 

**Abbreviations:** MIC<sub>90</sub>, minimum inhibitory concentration that inhibits the growth of 90% of indicated isolates (µg/mL); MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*; NA, not applicable; %R, percentage of resistant isolates; %S, percentage of susceptible isolates.

---

Table 2 Cumulative resistance profiles and MICs for CoNS isolates

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>CoNS All</th>
<th>%S</th>
<th>%R</th>
<th>MIC&lt;sub&gt;90&lt;/sub&gt;</th>
<th>MRCoNS</th>
<th>%S</th>
<th>%R</th>
<th>MIC&lt;sub&gt;90&lt;/sub&gt;</th>
<th>MSCoNS</th>
<th>%S</th>
<th>%R</th>
<th>MIC&lt;sub&gt;90&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vancomycin</td>
<td>1,475</td>
<td>100</td>
<td>0</td>
<td>2</td>
<td>717</td>
<td>100</td>
<td>0</td>
<td>2</td>
<td>758</td>
<td>100</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Besifloxacin</td>
<td>1,475 NA&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1</td>
<td>717 NA&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4</td>
<td>758 NA&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NA&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>1,475 68.9</td>
<td>31.1</td>
<td>16</td>
<td>717 48.5</td>
<td>51.5</td>
<td>32</td>
<td>758 88.1</td>
<td>11.9</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gatifloxacin</td>
<td>1,331 66.9</td>
<td>33.1</td>
<td>16</td>
<td>641 44.2</td>
<td>55.9</td>
<td>32</td>
<td>690 88.1</td>
<td>11.9</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>1,475 65.1</td>
<td>34.9</td>
<td>64</td>
<td>717 42.0</td>
<td>58.0</td>
<td>64</td>
<td>758 86.9</td>
<td>13.1</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>1,331 66.6</td>
<td>33.4</td>
<td>128</td>
<td>641 43.4</td>
<td>56.6</td>
<td>128</td>
<td>690 88.1</td>
<td>11.9</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>1,331 66.2</td>
<td>33.8</td>
<td>&gt;8</td>
<td>641 43.1</td>
<td>56.9</td>
<td>16</td>
<td>690 87.7</td>
<td>12.3</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azithromycin</td>
<td>1,475 38.8</td>
<td>61.2</td>
<td>&gt;512</td>
<td>717 21.8</td>
<td>78.2</td>
<td>&gt;512</td>
<td>758 54.9</td>
<td>45.1</td>
<td>&gt;512</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>1,331 98.8</td>
<td>1.2</td>
<td>8</td>
<td>641 98.4</td>
<td>1.6</td>
<td>8</td>
<td>690 99.1</td>
<td>0.9</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clindamycin</td>
<td>1,475 73.9</td>
<td>26.1</td>
<td>&gt;2</td>
<td>717 63.9</td>
<td>36.1</td>
<td>&gt;16</td>
<td>758 83.4</td>
<td>16.6</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methicillin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1,445</td>
<td>51.4</td>
<td>48.6</td>
<td>&gt;2</td>
<td>717 0</td>
<td>100</td>
<td>&gt;2</td>
<td>758 100</td>
<td>0</td>
<td>0.25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetracycline</td>
<td>381 86.1</td>
<td>13.9</td>
<td>&gt;16</td>
<td>176 82.4</td>
<td>17.6</td>
<td>&gt;16</td>
<td>205 89.3</td>
<td>10.7</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobramycin</td>
<td>1,475 83.1</td>
<td>17.0</td>
<td>8</td>
<td>717 72.3</td>
<td>27.8</td>
<td>32</td>
<td>758 93.3</td>
<td>6.7</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>1,331 72.1</td>
<td>28.0</td>
<td>&gt;128</td>
<td>641 58.4</td>
<td>41.7</td>
<td>256</td>
<td>690 84.8</td>
<td>15.2</td>
<td>128</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *Oxacillin was used as a surrogate for methicillin.* *Clinical and Laboratory Standards Institute interpretive breakpoints are not available.* 

**Abbreviations:** CoNS, coagulase-negative staphylococci; MIC<sub>90</sub>, minimum inhibitory concentration that inhibits the growth of 90% of indicated isolates (µg/mL); MRCoNS, methicillin-resistant coagulase-negative staphylococci; MSCoNS, methicillin-susceptible coagulase-negative staphylococci; NA, not applicable; %R, percentage of resistant isolates; %S, percentage of susceptible isolates.

---

were only notably resistant to azithromycin, higher levels of resistance to azithromycin, fluoroquinolones, tobramycin, and clindamycin were observed among MRSA isolates. Within the fluoroquinolone class, the MICs that inhibited the growth of 90% of isolates (MIC<sub>90</sub>) for all *S. aureus*, MRSA, and MSSA isolates were lower for the newer fluoroquinolones (besifloxacin, moxifloxacin, and gatifloxacin) compared to the older fluoroquinolones (ofloxacin, ciprofloxacin, and levofloxacin), with besifloxacin demonstrating the lowest MIC<sub>90</sub>s (all *S. aureus*: 1 µg/mL; MSSA: 0.25 µg/mL; and MRSA: 2 µg/mL). Vancomycin also demonstrated consistently low MIC<sub>90</sub>s among *S. aureus* (1 µg/mL for all, MRSA, and MSSA).
The majority of CoNS isolates collected were *S. epidermidis* (1,119 [75.9%]). As shown in Table 2, cumulative in vitro resistance among CoNS isolates was greatest to azithromycin (61.2%), methicillin (MR CoNS [MRCoNS]: 48.6%), and ciprofloxacin (34.9%), followed by trimethoprim (28.0%) and clindamycin (26.1%). Resistance to tobramycin and tetracycline was 17.0% and 13.9%, respectively, while chloramphenicol resistance was low (1.2%). Similar to MRSA isolates, higher rates of resistance were found among MRCoNS isolates when compared to MS CoNS (MSCoNS). As observed with *S. aureus*, MIC$_{90}$s were lower with newer fluoroquinolones as compared to older fluoroquinolones, and besifloxacin exhibited the lowest MIC$_{90}$s (all CoNS: 2 μg/mL; MSCoNS: 0.25 μg/mL; and MRCoNS: 4 μg/mL). Vancomycin MIC$_{90}$s were also consistently low among CoNS (2 μg/mL for all, MRCoNS, and MSCoNS).

Although high levels of in vitro resistance to azithromycin (35.9%) and penicillin (33.3%) were noted among *S. pneumoniae* isolates (Table 3), fluoroquinolone resistance was low (<1%). Among *S. pneumoniae* isolates, besifloxacin had the lowest MIC$_{90}$ of all tested antibiotics (0.06 μg/mL).

Isolates of *P. aeruginosa* were found to be generally susceptible to all antibiotics tested (Table 3), with low in vitro resistance to polymyxin B (8.6%), tobramycin (2.5%), and the fluoroquinolones (5.2%–7.4%). MIC$_{90}$ was the lowest for ciprofloxacin (0.5 μg/mL).

Similarly, *H. influenzae* isolates belonged to nearly all susceptible to the antibiotics tested (Table 3), with only 2.5% and <1% in vitro resistance observed for tetracycline and the fluoroquinolones, respectively. The MIC$_{90}$s for tested antibiotics were no greater than 0.03 μg/mL for the fluoroquinolones, 0.5 μg/mL for tetracycline and chloramphenicol, and 2 μg/mL for azithromycin.

### Multidrug resistance among staphylococci
Since methicillin resistance is often an indication of concurrent resistance to other antibiotic classes, we summarized the percentage of multidrug resistance among staphylococcal isolates (Figure 1). Overall, in vitro multidrug resistance was observed in 542 (32.0%) *S. aureus* isolates and 601 (40.7%) CoNS isolates. Rates of multidrug resistance were much higher among MR staphylococci than MS isolates, with 473 (76.2%) MRSA isolates and 527 (73.5%) MRCoNS isolates exhibiting resistance to ≥3 antibiotic classes, compared to 69 (6.4%) MSSA isolates and 72 (9.5%) MSCoNS isolates. Although more likely to be multidrug resistant, all MRSA and MRCoNS isolates were susceptible to vancomycin.

### Antibiotic resistance rates by patient’s age
Patient’s age was known for 550 (14.0%) MRSA, 865 (22.0%) MSSA, 564 (14.3%) MRCoNS, 612 (15.6%) MSCoNS, 509 (12.9%) *P. aeruginosa*, 460 (11.7%) *H. influenzae*, and 374 (9.5%) *S. pneumoniae* isolates. Analysis of the mean percentage of in vitro resistance by patient’s age categorized by decade of life showed differences among *S. aureus* (P<0.0001), CoNS (P<0.0001), *P. aeruginosa* (P=0.0469), and *S. pneumoniae* (P=0.0172). For *S. aureus*, pairwise differences were evident between patients aged ≥80 years (≥35.2% resistance) and those aged <80 years (resistance between 14.3% and 26.9%). Among CoNS, pairwise differences in resistance were identified in patients aged ≥70 years (≥31.3%)
vs those aged 10–19, 20–29, and 50–59 years (18.6%, 19.6%, and 23.0%, respectively), as well as in patients aged 80–89 years (32.5%) vs 30–39 years (22.8%). When Tukey’s HSD test used the $P<0.1$ criterion for statistical significance, pairwise differences were observed between patients aged 20–29 years (2.2% resistance) and those aged 50–59 years (10.4% resistance) among $P. aeruginosa$ isolates; however, no pairwise differences were identified for $S. pneumoniae$.

Consistent with the mean percentage of resistance findings, significant differences were found in in vitro methicillin resistance specifically for $S. aureus$ and CoNS based on patient’s age by decade of life ($P<0.0001$ for both; Figure 2). In general, methicillin resistance appeared higher in older age groups.

**Longitudinal trends in antibiotic resistance**

Figure 3 presents in vitro rates of methicillin resistance among staphylococci over the 8 years of the ARMOR study. Methicillin resistance in $S. aureus$ ranged from 23.4% to 50.0%, whereas methicillin resistance in CoNS ranged from 42.9% to 57.0%. While a small but significant decrease in resistance to methicillin was reported among $S. aureus$ isolates ($P<0.0001$), methicillin resistance did not decrease for CoNS over the 8-year time frame.

Figure 4 presents trends in in vitro antibiotic resistance over the 8 years of the ARMOR study for other antibiotics among $S. aureus$, MRSA, CoNS, MRCoNS, $S. pneumoniae$, and CoNS.
and *P. aeruginosa*. Longitudinal trends varied among staphylococci. Resistance to azithromycin (*P*<0.0001), chloramphenicol (*P*=0.0042), ciprofloxacin (*P*<0.0001), and tobramycin (*P*<0.0001) decreased significantly among *S. aureus* isolates. Among CoNS isolates, a decrease in resistance to ciprofloxacin (*P*=0.0009) and a significant increase
Figure 4  Trends in antibiotic resistance over time (ARMOR, 2009–2016).

Notes: Trends in antibiotic resistance over 8 years of ARMOR are shown for representative antibiotics for which systemic breakpoints were available. Significant changes \( (P < 0.05, \text{bold font}) \) in antibiotic resistance trends over time were observed.

Abbreviations: ARMOR, Antibiotic Resistance Monitoring in Ocular microorganisms; CoNS, coagulase-negative staphylococci; MRCoNS, methicillin-resistant coagulase-negative staphylococci; MRSA, methicillin-resistant \( S. \) aureus.

in resistance to trimethoprim \( (P = 0.0246) \) were observed. Among MR staphylococcal isolates, significant differences in the rates of tobramycin resistance were observed over time; increasing resistance was observed among MRCoNS isolates \( (P = 0.0077) \), while decreasing resistance was observed among MRSA isolates \( (P = 0.0035) \).

Among \( P. \) aeruginosa isolates, significant decreases in ciprofloxacin \( (P = 0.0126) \) and tobramycin \( (P = 0.0183) \) resistance were observed over the course of the study. Resistance among \( S. \) pneumoniae isolates remained consistent, with no discernable changes over time.

Discussion

The ARMOR surveillance study examines in vitro antibiotic susceptibility/resistance profiles among common ocular pathogens collected prospectively from sites across the United States.\(^2^9\) While several single-center studies have reported in vitro antibiotic resistance rates among ocular
isolates, ARMOR is the only ongoing study to do so on a nationwide scale. With almost 5,000 isolates included, the present report evaluates cumulative resistance rates and trends in resistance over 8 years of the ARMOR study, expanding on previously published 5-year and 7-year analyses. Current ARMOR results demonstrate substantial levels of in vitro resistance to commonly used antibiotics, particularly among staphylococcal isolates, of which nearly half were MR. Multidrug resistance analyses showed approximately two in every five staphylococcal isolates and approximately three in every four MRSA or MRCoNS isolates exhibited in vitro resistance to three or more antibiotic classes. Higher levels of overall mean in vitro resistance were found among isolates from elderly patients, especially when considering methicillin resistance among staphylococci. Isolates of S. pneumoniae showed high levels of in vitro resistance (~35%) to azithromycin and to oral penicillin, but were susceptible to fluoroquinolones and other tested drugs. Conversely, resistance among P. aeruginosa and H. influenzae remained low (<9%) against almost all antibiotics tested. Significant declines in in vitro resistance were observed for many antibiotic-pathogen combinations, including a decrease in methicillin resistance among S. aureus, although an increase in trimethoprim resistance was seen among CoNS isolates.

Results from the current analysis are generally consistent with recent reports on the prevalence of in vitro methicillin resistance among staphylococci from ocular infections in the United States, with some variations. Miller reported similar levels of methicillin resistance among 967 S. aureus and 287 S. epidermidis isolates from ocular infections collected at the Bascom Palmer Eye Institute between 2011 and 2015 (42.1% and 46.3%, respectively), in line with the current study. However, in an analysis of ocular pathogen data collected at Mount Sinai Hospital (2010–2015), which included 113 S. aureus isolates, a lower rate of MRSA (~25%) was observed; although a trend towards decreasing MRSA prevalence over the 6-year study period was noted (31.3% in 2010 to 14.1% in 2015), the change was not statistically significant. It is unclear whether the differences observed between studies reflect regional variations among predominant infective strains or are representative of a temporal decline in MRSA prevalence among ocular infections. Nonetheless, patterns of resistance among staphylococci to fluoroquinolones, macrolides, and other antibiotic agents (when tested) were similar to the current ARMOR analysis in these studies, with MR isolates exhibiting increased resistance compared to MS isolates.

As previously reported, large differences in MIC$_{90}$ values for staphylococci were evident within the fluoroquinolone class of drugs, with older fluoroquinolones having higher MIC$_{90}$ values compared to newer ones. Besifloxacin had the lowest MIC$_{90}$ values among staphylococci regardless of methicillin phenotype, attesting to its potent in vitro activity. Due to the lack of a systemic besifloxacin formulation, interpretive criteria are not available to categorize bacterial isolates as susceptible or resistant to besifloxacin. In the absence of such breakpoints, evaluation of besifloxacin MIC data alongside that of comparator agents allows for an assessment of its in vitro potency; however, the clinical relevance of these findings is unknown. Previous studies have shown besifloxacin to provide balanced, potent inhibition of both bacterial DNA gyrase and topoisomerase, with minimum bactericidal concentrations generally within one dilution of the MIC. The lack of any meaningful changes in besifloxacin MIC$_{90}$ values for all study species over the 8-year period suggests its activity has remained stable over time and may be a reflection of that balanced inhibition. Of note, all staphylococcal isolates were susceptible in vitro to vancomycin, which had similar MIC$_{90}$s to those for besifloxacin. The absence of vancomycin resistance and correspondingly low vancomycin MIC$_{90}$s is particularly reassuring given that vancomycin is commonly compounded for ophthalmic use in the treatment of resistant ocular infections.

In terms of microbial resistance by patient age, the rates of overall mean resistance, and specifically methicillin resistance, were higher in older patients, consistent with previous ARMOR data analyses and other studies. ARMOR data analyses and other studies. This association may be because older patients often spend more time in hospitals and health care centers, and are, therefore, more likely than younger patients to be exposed to antibiotic-resistant bacteria common in these environments. Relationships between antibiotic resistance rates and patient age have also been reported in studies of systemic infections. A recent retrospective survey of data from 511 MRSA cases collected between 2008 and 2009 found that greater rates of resistance were observed among older patients for fluoroquinolones but not with other antibiotic classes.

Analysis of resistance rates over time showed decreasing trends for in vitro resistance, which is promising and generally consistent with earlier ARMOR study reports, with few exceptions. The current analysis found decreases in resistance to ciprofloxacin (among S. aureus, CoNS, MRCoNS, and P. aeruginosa) and tobramycin (among S. aureus, MRSA, and P. aeruginosa), as well as to azithromycin and chloramphenicol (among S. aureus). Of particular note, a decrease...
in methicillin resistance was observed among isolates of *S. aureus*, but not CoNS, in the present study; this decline was not evident early in the ARMOR study, but was detected in the 7-year trend analysis and has continued over the current 8-year time frame. Additionally, the significant increase in trimethoprim resistance among CoNS seen in this study was not reported previously.

In vitro resistance rates and susceptibility profiles in the present study are similar to reported data for bacterial isolates with specific ocular diagnoses, such as conjunctivitis, keratitis, and endophthalmitis. In a 20-year review of antibiotic resistance among *S. aureus* keratitis isolates (1993–2012), all were susceptible to vancomycin, and fluoroquinolone resistance was prevalent, with MRSA representing 30.7% of the total. A study assessing rates of antibiotic sensitivity among 998 isolates collected over 25 years (1987–2011) from endophthalmitis cases also identified substantial resistance to fluoroquinolones in gram-positive isolates and a decreasing trend in resistance to aminoglycosides, including tobramycin. However, findings from that study indicated an increase in methicillin resistance over time (from 18% and 31% among *S. aureus* and *S. epidermidis*, respectively, to >50% each), in contrast to the present ARMOR analysis.

In addition, current ARMOR results are generally consistent with antibiotic resistance rates observed in surveillance studies for non-ocular infections requiring systemic antibiotic treatment. The Linezolid Experience and Accurate Determination of Resistance (LEADER) program recently reported high methicillin resistance rates among 3,031 (46%) *S. aureus* and 924 (59%) CoNS isolates collected primarily from bloodstream, respiratory tract, and skin and soft tissue infections in the United States between 2011 and 2015, with ~60% and upwards of 70% of MR staphylococci exhibiting resistance to fluoroquinolones and macrolides, respectively. Likewise, the latest United States report of 21,056 clinical *S. aureus* isolates tested in the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) study from 2010 to 2016 found methicillin resistance rates decreased from 50.0% to 42.2%; >65% of MRSA isolates showed resistance to fluoroquinolones and macrolides over the 7-year period. Staphylococcal resistance rates for clindamycin and tetracycline in the LEADER and AWARE studies were similar to those observed in the current study. Resistances among *S. pneumoniae* isolates in these studies were also largely consistent with those in the ARMOR study; oral penicillin and macrolide resistance rates were, respectively, 36.8% and 42.9% in LEADER (n=850) and 41.3% and 44.6% in AWARE (n=8,768), compared to 33.3% and 35.9% in the present analysis. Further comparisons of data from systemic infections with ARMOR results were hindered by differences in the antibiotic agents tested between studies.

Resistance trends based on source of isolate by geography for this 8-year dataset were recently published elsewhere and showed differences in antibiotic resistance rates based on geographic region. Significant trends were noted for *S. aureus* (high in the South [28.1%]; low in the West [16.8%]), *S. pneumoniae* (high in the Midwest [14.5%]; low in the West [7.6%]), and *P. aeruginosa* (high in the Midwest [8.5%]; low in the West [2.9%]), with no regional differences found among CoNS and *H. influenzae* isolates. While the underlying reasons for observed geographic disparities have yet to be elucidated, it is possible that climate variations and/or differences in prescribing patterns and antibiotic stewardship programs may impact regional antibiotic resistance rates.

The current analysis of ARMOR has several limitations. The study evaluated in vitro resistance rates in ocular pathogens based on systemic breakpoints, which were established based on pharmacokinetic and pharmacodynamic data obtained following systemic administration of antibiotics. Currently, associations between systemic breakpoints and topical antibiotic concentrations used in ocular infections have not been determined. It is assumed that concentrations achieved at the site of infection after topical ophthalmic use are at least as high as, if not higher than, those achieved after systemic administration. However, blinking and tear turnover, along with barriers to ocular penetration, work to decrease antibiotic concentrations following topical ophthalmic use. Another limitation is the potential for sampling bias due to the infrequent practice of culturing bacterial pathogens. With the exception of intraocular infections, ocular cultures are seldom collected during routine clinical practice, and infections are generally treated empirically. As a result, cultures, when collected, may be representative of more severe infections that do not respond to initial empirical treatment.

**Conclusion**

Results from this analysis of 8-year ARMOR data demonstrate small trends in antibiotic resistance, with encouraging decreases noted in rates of resistance to certain antibiotics. However, rates of antibiotic resistance among gram-positive organisms remain high, especially for methicillin resistance and multidrug resistance among staphylococci. These findings are consistent with published studies in the scientific literature for both ocular and non-ocular staphylococcal infections. These data can assist health care practitioners in...
making informed choices regarding the treatment of ocular infections with ophthalmic antibiotics.

Data availability
The presented data are from the ARMOR study and are available from the corresponding author upon request as appropriate.

Acknowledgments
Editorial assistance was provided by Christine M. Sanfilippo, PhD, an employee of Bausch & Lomb Incorporated.

The ARMOR study is funded by Bausch & Lomb Incorporated, which was responsible for the design and conduct of the study, as well as data collection, management, and analysis. Medical writing support was provided by Cactus Communications, Inc., and was funded by Bausch & Lomb Incorporated.

Author contributions
All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
RKT has received advisory board/consultancy fees from Bausch & Lomb Incorporated. PAA has received grants, advisory board/consultancy fees, and non-financial support from Bausch & Lomb Incorporated. The authors report no other conflicts of interest in this work.

References


37. Besivance® (besifloxacin ophthalmic suspension) 0.6% [prescribing information]. Bridgewater, NJ: Bausch & Lomb Incorporated; June 2016.


